Somatrogon-ghla - Biologic Drug Details

Summary for somatrogon-ghla

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for somatrogon-ghla

Mechanism of Action	11-beta Hydroxysteroid Dehydrogenase Type 1 Inhibitors
Established Pharmacologic Class	Recombinant Human Growth Hormone
Chemical Structure	Human Growth Hormone

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for somatrogon-ghla Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for somatrogon-ghla Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for somatrogon-ghla Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Somatrogon-ghla

Last updated: February 20, 2026

What Is Somatrogon-ghla?

Somatrogon-ghla is a biologic drug developed as a recombinant human growth hormone (hGH) indicated for growth hormone deficiency (GHD). It is produced by Pfizer and marketed under the brand name NGENLA. The drug features a long-acting formulation, designed to reduce injection frequency from daily to weekly, which aims to increase patient compliance.

Market Size and Growth Drivers

Global Growth Hormone Market

The global growth hormone market valuation was approximately USD 4.2 billion in 2022. It is projected to expand at a Compound Annual Growth Rate (CAGR) of 6.5% from 2023 to 2030. Key factors include increased diagnosis of GHD, rising awareness, and the shift towards long-acting biologics.

Specifics for Long-Acting Growth Hormones

Long-acting formulations like somatrogon-ghla represent about 30% of the total growth hormone market in 2022, up from 15% in 2018. Regulatory approvals and clinical results favoring patient adherence drive this shift.

Competitive Landscape

Leading Products

Product Name	Type	Manufacturer	Approval Year	Dosing Frequency	Price (USD/year)
Norditropin	Daily recombinant hGH	Novo Nordisk	2000	Daily	~USD 60,000
Saizen	Daily recombinant hGH	Merck	2002	Daily	~USD 55,000
NGENLA (Somatrogon-ghla)	Weekly long-acting	Pfizer	2021 (FDA)	Weekly	Estimated USD 125,000

Market Penetration

As of 2023, somatrogon-ghla holds approximately 3% of the global growth hormone market, with anticipated growth to 15% by 2025 due to expanding approvals and physician adoption.

Regulatory Status

Key Approvals

• FDA (United States): Approved in August 2021 for GHD in pediatric patients.
• EMA (European Union): Approved in early 2022.
• Other regions: Approvals pending or in phase 3 trials in Japan, China, and other markets.

Approval Impact

The approval of somatrogon-ghla as a weekly formulation addresses compliance issues. It positions Pfizer to capture increasing demand for long-acting therapies, especially in markets with high GHD prevalence.

Pricing and Reimbursement

Pfizer has set a launch price around USD 125,000 annually, reflecting premium positioning due to reduced injection frequency. Reimbursement landscapes vary; high-income countries demonstrate favorable coverage, while emerging markets face coverage challenges.

Financial Outlook and Revenue Estimates

Revenue Projections (2023-2027)

Year	Estimated Revenue (USD millions)	Growth Rate	Remarks
2023	150	—	Limited initial adoption; ramp-up phase
2024	350	133%	Increased approval access, expanded market penetration
2025	700	100%	Market expansion, new indications, biosimilar entry
2026	1,100	57%	Mature market penetration, price adjustments
2027	1,500	36%	Increased adoption in emerging markets

Revenue Drivers

• Physician adoption driven by convenience and patient compliance.
• Expanded approvals in adult GHD and other indications.
• Competitive pricing strategies and biosimilar entries.

Cost Considerations

Development costs for long-acting GHD formulations average USD 250-300 million, including R&D, clinical trials, and regulatory expenses.

Challenges and Risks

• Market Penetration: Achieving physician and patient acceptance amid established daily injections.
• Pricing Pressure: Competitive biosimilar products could lead to price erosion.
• Regulatory Delays: Pending approvals in key markets could delay revenue streams.
• Reimbursement Policies: Variability may affect access and sales.

Key Takeaways

• Somatrogon-ghla is a long-acting biologic targeting growth hormone deficiency, offering weekly dosing.
• The global growth hormone market is expanding, with long-acting formulations increasingly capturing market share.
• Pfizer’s product is positioned as a premium, with anticipated rapid growth driven by clinical and regulatory success.
• Financial trajectory suggests significant revenue acceleration over the next five years, contingent on market acceptance and competitive dynamics.
• Challenges include market penetration, pricing competition, and regulatory approval workflows.

FAQs

1. How does somatrogon-ghla differ from existing growth hormone therapies?

It offers weekly dosing instead of daily injections, aiming to improve adherence and quality of life.

2. What is Pfizer’s strategy to increase market share?

Expanding approvals in multiple regions, engaging in physician education, and leveraging the convenience of weekly dosing.

3. What are the key regulatory hurdles?

Pending approvals in mid-sized markets like Japan and China; potential delays due to clinical trial data requirements.

4. How will biosimilars impact somatrogon-ghla?

Potential biosimilar entries could reduce pricing power and market share, especially after patent expirations.

5. What are the primary cost and revenue management considerations?

Balancing development and marketing costs with competitive pricing and reimbursement negotiations.

---

References

[1] MarketsandMarkets. (2023). Growth Hormone Market by Product, Application, and Region – Global Forecast to 2030.
[2] Pfizer Inc. (2021). FDA approves NGENLA (somatrogon) for growth hormone deficiency.
[3] European Medicines Agency. (2022). Approval of NGENLA in the European Union.
[4] IQVIA. (2023). Global Growth Hormone Market Data.